Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use.

Breast Cancer Res · 2021 · PMC8285794 · PMID 34274003

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A similar observation was made when using BCSS although the association in low-risk patients did not reach statistical significance (Additional file 2 – Table 1).

also in 111,027 other papers

a slightly increasing trendno p-value reported

However, a slightly increasing trend in Oncotype DX testing was observed in stage III breast cancer patients, starting from 0% in 2004 to 6% in 2015 (Fig. 1 B).

also in 801 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.